Search Results

AavantiBio today announced the formation of its Scientific Advisory Board (SAB) and its members.

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the closing of its acquisition of AavantiBio, a privately held gene therapy company focused on transforming the lives of patients with Friedreich’s ataxia and rare cardiomyopathies, including its pipeline assets and net cash.

AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference.

• Collaboration to Support AavantiBio’s Diverse Gene Therapy Pipeline; Development and Supply of GMP Cell Lines and Viral Banks • Agreement to Include Manufacture and Supply of Material for GLP Tox Studies and Clinical Trial for Friedreich’s Ataxia Patients

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the results of the special meeting of the stockholders held on December 1, 2022.

AavantiBio today announced it is partnering with the University of Florida to research and develop next generation gene therapy capsids with the goal of creating safer, more effective, and tissue specific gene therapies.

AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, and Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins and mRNA for the biotech industry, announced a long-term strategic partnership for the supply of plasmid DNA that will enable AavantiBio to advance its platform of innovative gene transfer therapies.

AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Christopher Wright, M.D., Ph.D., as Chief Medical Officer.

AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, announced the appointment of Jessie Hanrahan, Ph.D. as Chief Regulatory Officer.

AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced new additions to its leadership team with the appointments of Paul Herzich as Chief Technology Officer and Jared Simons as Vice President of Manufacturing.